A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Stage III Non-small-cell Lung Cancer Clinical Trial

Official title:
A Randomized, Double-blind and Imitation, Placebo Parallel Control, Multicentre Phase III Study of TQB2450 With or Without Anlotinib as Consolidation Treatment in Subjects With Locally Advanced/Unresectable (Stage III) Non-Small Cell Lung Cancer That Have Not Progressed After Prior Concurrent/Sequential Chemoradiotherapy

Status Recruiting

Clinical Trial Summary

This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as consolidation treatment in subjects with locally advanced/unresectable (Stage III) Non-Small Cell Lung Cancer that has not progressed after prior concurrent/sequential chemoradiotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Stage III Non-small-cell Lung Cancer

Clinical Trial Details

NCT number	NCT04325763
Study type	Interventional
Source	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact	Ming Chen
Phone	0571-88122508
Email	chenming@zjcc.org.cn
Status	Recruiting
Phase	Phase 3
Start date	May 27, 2020
Completion date	March 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04085250` - Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy	Phase 2
Recruiting	`NCT03742687` - Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC	N/A
Completed	`NCT01733589` - Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT03589547` - Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung	Phase 2
Not yet recruiting	`NCT04304638` - Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
Active, not recruiting	`NCT01576796` - Radiotherapy Dose Complement in the Treatment of Hypoxic Lesions Patients With Stage III Non-small-cell Lung Cancer	Phase 2
Recruiting	`NCT04441138` - Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC	Phase 2
Not yet recruiting	`NCT04181372` - A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer	Phase 2
Terminated	`NCT03871153` - Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer	Phase 2
Completed	`NCT05331833` - Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.